interferon - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %some concernnot evaluable moderatecrucial-
deaths 0.99 [0.73, 1.34]< 19%9 studies (9/-)51.9 %some concernserious moderatecrucial-
clinical deterioration 0.50 [0.19, 1.33]< 10%2 studies (2/-)91.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.71 [1.30, 2.26]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 3.29 [1.50, 7.20]> 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.42 [1.70, 6.88]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.83 [0.41, 8.14]> 10%1 study (1/-)78.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.71 [1.31, 2.24]> 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.83 [0.35, 1.93]< 146%2 studies (2/-)67.1 %some concernnot evaluable moderateimportant-
hospital discharge 1.97 [0.84, 4.60]> 10%2 studies (2/-)94.1 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.74 [0.34, 1.62]< 10%4 studies (4/-)77.6 %some concernnot evaluable moderateimportant-
viral clearance 1.76 [0.51, 6.05]> 166%3 studies (3/-)81.5 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.17 [0.56, 2.48]> 184%2 studies (2/-)66.2 %some concernnot evaluable moderateimportant-
viral clearance by day 14 3.13 [0.61, 15.98]> 153%2 studies (2/-)91.4 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.23 [1.08, 4.61]> 10%2 studies (2/-)98.5 %some concernnot evaluable moderateimportant-
ICU admission 0.49 [0.24, 1.00]< 10%3 studies (3/-)97.4 %some concernnot evaluable moderatenon important-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.99 [0.17, 5.88]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-
adverse events 1.41 [0.74, 2.67]< 10%2 studies (2/-)14.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.